Vitiligo is the most common disorder of pigmentation occurring with a frequency of 0.1-2.0% in various populations. It is an organ-specific autoimmune disease of the skin. The cutaneous depigmentation is usually patchy with a tendency to affect symmetrical areas of the skin at corresponding anatomical sites on each side of the body. The disease has been noted in increased frequency in patients and their relatives affected by other autoimmune endocrinopathies. 1 We report the case of a 52-year-old female who was diagnosed with acute myelogenous leukemia (FAB: M1). She underwent standard induction chemotherapy with idarubicin and cytarabine and consolidation with highdose cytarabine, and achieved complete remission. The patient's disease relapsed one and a half years later. She received reinduction and consolidation chemotherapy, followed by high-dose chemotherapy with busulfan and cytoxan and an HLA-identical allogeneic stem cell transplant. Both donor and recipient were seropositive for cytomegalovirus (CMV).
The patient had no cutaneous lesions prior to transplant. Her sister (the donor), however, had vitiligo for several years involving mainly the perioral region, with few scattered lesions on the extremities.
At 1-month post transplant, the patient presented with an erythematous rash, which clinically was consistent with graft-versus-host disease (GVHD) of the skin. She was treated with prednisone and triamcinolone cream. About 1 month later, she was noted to have elevated CMV antigenemia and was treated with foscarnet. At her 6-month and 1-year evaluation, chimerism study revealed 95% donor and 5% recipient cells.
At 18 months post transplant the patient presented with patchy depigmentation of the skin involving her face, trunk, upper and lower extremities. Skin biopsy revealed minimal perivascular lymphocytic infiltrate with minimal basal vacuolization compatible with mild GVHD (Figure 1) . Immunosuppression with cyclosporine and prednisone was instituted as well as prophylactic antibiotics. Evaluation 1 month later showed no change in skin pigmentation prompting consultation with a dermatologist. The dermatologist concluded that the patient did not have GVHD but vitiligo. The patient's disease was noted to be more diffuse than that of her sister.
While vitiligo can mimic skin GVHD, the lack of response to standard therapy for GVHD and the pathologic findings on the skin biopsy led to the conclusion that the patient had acquired vitiligo through peripheral stem cell transplant.
The exact etiology of vitiligo is unknown; however, there is evidence to suggest that it is most likely due to lymphocyte-mediated destruction of melanocytes occurring by both humoral-and cell-mediated mechanisms. Naughton et al 2 showed that antimelanocyte antibodies were present in vitiligo patients. Sera from patients with vitiligo were shown to react with melanocyte surface and cytoplasmic antigens.
3,4 Yao-Hua Song et al 5 showed that tyrosinase, an enzyme important in melanin formation, is a principal auto antigen of autoimmune vitiligo. WankowiczKalinsha et al 6 found increased amounts of melanocytereactive cytotoxic T cells in the peripheral blood of patients with vitiligo and were able to show a correlation between perilesional T-cell infiltration and melanocyte loss in situ, suggesting the possible role of cellular immunity in the pathogenesis of the disease. It is clear that the cause of this skin disorder is multifactorial.
A review of the literature revealed that all of the cases reported of vitiligo after stem cell/bone marrow transplant or after donor lymphocyte infusion, occurred in patients who had developed GVHD. GVHD was mild, grade I in some cases and more severe, up to grade III in others. In allogeneic stem cell transplant the patient and donor are usually matched for the MHC Class I (A, B) and MHC Class II (DR) antigens. GVHD could, therefore, occur due to mismatch of minor histocompatibility antigens. 7 The development of GVHD is a multistep process in which the recipient tissues are recognized as foreign by the donor immune system, leading to the activation and expansion of various effector populations ultimately leading to T-cellmediated direct cytotoxic damage of target tissues.
In this patient, we hypothesize that GVHD was most likely the inciting factor leading to the production of melanocyte-specific cytotoxic T cells and the development of vitiligo several months later. This case is unusual in that vitiligo presented one and a half years after stem cell transplantation.
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